Wedbush analyst Robert Driscoll downgraded Alpine Immune Sciences (ALPN) to Neutral from Outperform with a price target of $65, up from $47, after the company agreed to an acquisition by Vertex Pharmaceuticals (VRTX) for $65 per share, or $4.9B in cash. The firm expects the acquisition to close.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALPN: